CJC-1295 With and Without DAC: Complete Research Guide and Comparison

CJC-1295: Complete Research Guide with DAC vs Non-DAC Comparison

CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analogue that has become one of the most widely researched peptides for growth hormone secretion studies. Available in two primary formulations—with and without Drug Affinity Complex (DAC)—this compound offers different pharmacokinetic profiles suited to varying research protocols. Understanding the distinctions between CJC-1295 with DAC and without DAC is essential for designing effective research studies.

What is CJC-1295?

CJC-1295 is a 30-amino acid synthetic peptide that mimics the physiological action of endogenous GHRH, developed to overcome the limitations of native GHRH (short half-life, rapid degradation) by introducing modifications that extend bioavailability while maintaining receptor specificity.

• Amino Acid Count: 30 amino acids
• Peptide Class: GHRH analogue (tetrasubstituted)
• Receptor Target: GH-releasing hormone receptor (GHRHR)
• Primary Effect: Stimulates pituitary GH secretion

CJC-1295 Without DAC vs. With DAC: Key Differences

CJC-1295 Without DAC (Modified GRF 1-29)

• Half-Life: 30-60 minutes
• Peak GH Response: 30-90 minutes post-injection
• Duration of Action: 2-4 hours
• Advantages: More physiological pulse pattern; flexible dosing; rapid onset; suitable for combination studies with ipamorelin

CJC-1295 With DAC (Drug Affinity Complex)

DAC is an albumin-binding modification that extends peptide half-life by attaching to serum albumin, creating a depot effect.

• Half-Life: 6-8 days
• Peak GH Response: 1-4 days post-injection
• Duration of Action: Continuous elevation for 7-14 days
• Advantages: Once-weekly dosing; sustained baseline GH elevation; superior long-term protocol compliance

Research Data

• Without DAC: 2-5x baseline GH elevation; peaks at 30-90 minutes
• With DAC: Sustained 1.5-3x baseline GH elevation for 7-14 days post-injection
• Both formulations show dose-dependent effects (2-100 µg/kg range)
• Combination with ipamorelin: Synergistic GH response 5-10× above baseline via dual GHRHR + GHS-R1a pathway activation

Pharmacokinetic Summary

CJC-1295 and Ipamorelin Synergy

A common research strategy combines CJC-1295 (GHRH pathway via GHRHR) with ipamorelin (ghrelin pathway via GHS-R1a) for synergistic GH stimulation. Dual pathway stimulation increases GH secretion 5–10× over baseline, dramatically exceeding either compound alone. Pre-mixed blends are available for convenience.

Where to Buy CJC-1295 for Research

• HPLC purity ≥99% with sequence-confirmed COA
• Mass spectrometry identity confirmation
• Both DAC and non-DAC variants from same supplier for comparative studies

HPLC Verified

CJC-1295 Without DAC 5mg

Purity: 99%+ HPLC

Half-Life: 30–60 min

Format: Lyophilized

$45

Buy Now

HPLC Verified

CJC-1295 With DAC 10mg

Purity: 99%+ HPLC

Half-Life: 6–8 days

Format: Lyophilized

$65

Buy Now

HPLC Verified

Ipamorelin / CJC-1295 Blend 10mg

Purity: 99%+ HPLC

Synergy: Dual pathway

Format: Lyophilized

$120

Buy Now

Research Disclaimer: This product is sold strictly for in vitro research and laboratory use only. Not for human consumption. Not medical advice.